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Inflammatory mechanisms are proposed to play a
significant role in the pathogenesis of pulmonary ar-
terial hypertension (PAH). Previous studies have de-
scribed PAH in fat-fed apolipoprotein E knockout
(ApoE/) mice. We have reported that signaling in
interleukin-1–receptor–knockout (IL-1R1/) mice
leads to a reduction in diet-induced systemic athero-
sclerosis. We subsequently hypothesized that double-
null (ApoE//IL-1R1/) mice would show a re-
duced PAH phenotype compared with that of
ApoE/ mice. Male IL-1R1/, ApoE/, and
ApoE//IL-1R1/ mice were fed regular chow or
a high-fat diet (Paigen diet) for 8 weeks before phe-
notyping for PAH. No abnormal phenotype was ob-
served in the IL-1R1/ mice. Fat-fed ApoE/ mice
developed significantly increased right ventricular
systolic pressure and substantial pulmonary vascu-
lar remodeling. Surprisingly, ApoE//IL-1R1/
mice showed an even more severe PAH phenotype.
Further molecular investigation revealed the ex-
pression of a putative, alternatively primed IL-1R1
transcript expressed within the lungs but not aorta
of ApoE//IL-1R1/ mice. Treatment of ApoE/
and ApoE//IL-1R1/mice with IL-1–receptor an-
tagonist prevented progression of the PAH pheno-
type in both strains. Blocking IL-1 signaling may
have beneficial effects in treating PAH, and alterna-
tive IL-1–receptor signaling in the lung may be im-portant in driving PAH pathogenesis. (Am J Pathol
2011, 179:1693–1705; DOI: 10.1016/j.ajpath.2011.06.037)
Pulmonary arterial hypertension (PAH) is a life-threaten-
ing condition with high morbidity and mortality.1 Progres-
sive pulmonary vascular remodeling that is characterized
by disorganized cellular proliferation leads to an increase
in pulmonary artery pressure, right ventricular hypertro-
phy, failure, and death.2–6 Recent evidence has high-
lighted a link between the metabolic syndrome and as-
sociated insulin resistance with PAH.7 The importance of
peroxisome proliferator-activated receptor  (PPAR)
signaling (which is associated with insulin resistance) in
PAH was shown by Hansmann et al8 when describing
PAH in Western diet–fed apolipoprotein E–deficient mice
(ApoE/). Treatment with a PPAR agonist reversed dis-
ease in this model and mice with the targeted deletion of
PPAR in either endothelial or smooth muscle cells de-
velop PAH. Further work subsequently has linked this
mechanism to aberrant bone morphogenetic protein
(BMP), platelet-derived growth factor signaling, and re-
duced adiponectin.9
Interactions between inflammatory signaling and vas-
cular cells are a key aspect of vascular injury/repair and
disease and are considered to have an important role in
the pathogenesis of PAH. Previous studies have shown
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AJP October 2011, Vol. 179, No. 4that numerous inflammatory cytokines, including those
from the interleukin family, are up-regulated in PAH.10–12
Interestingly, overexpression of IL-6 in the lungs of mice
is sufficient to induce an increase in right ventricular
systolic pressure (RVSP), pulmonary vascular remodel-
ing, and right ventricular hypertrophy (RVH).13 Further-
more, treatment of rats with the naturally occurring IL-1–
receptor antagonist (IL-1ra) has been shown to protect
against the development of monocrotaline-induced PAH,
although interestingly not against hypoxia-induced
PAH.14 In in vitro studies, PPAR inhibits IL-1–stimulated
proliferation and migration of vascular smooth muscle
cells via up-regulation of IL-1ra,15 further supporting the
concept that the IL-1 pathway also may be an important
link between PPAR signaling and PAH.
Our group recently showed that feeding a high-fat,
high-cholate diet (Paigen diet) to ApoE/ mice for 8
weeks doubled the atherosclerotic lesion size in the aor-
tic sinus compared with mice fed a high-fat (Western)
diet. Furthermore, Paigen diet–fed mice that were doubly
deficient for both ApoE and the IL-1–receptor type 1
(IL-1R1) (ApoE//IL-1R1/) had a significantly reduced
lesion size and lower systemic blood pressure compared
with ApoE/mice on the same diet.16 Because mice fed
a Western diet have been shown to develop pulmonary
hypertension, we hypothesized the following: feeding
ApoE/ mice the Paigen diet for 8 weeks would induce
a more severe form of PAH than previously reported with
the Western diet; given the known links with inflammation
and PAH, ApoE//IL-1R1/ mice would show a re-
duced or protected PAH phenotype.
We report here that Paigen diet–fed ApoE/ mice
develop moderately severe PAH with obliterative pulmo-
nary vascular remodeling. Surprisingly, ApoE//IL-
1R1/ mice showed a more severe phenotype showing
lesions with dysregulated elastin, subsequent medial hy-
pertrophy, and neointimal formation similar to that found
in the human disease. After further investigation into po-
tential molecular mechanisms, we discovered a putative,
alternatively primed IL-1R1 transcript17 expressed within
the lungs of the ApoE//IL-1R1/ double-null mice.
Treatment of ApoE/ and ApoE//IL-1R1/ mice with
IL-1ra, as disease was developing, prevented an in-
creased RVSP and pulmonary vascular remodeling in
both models, suggesting that targeting IL-1 may have
potential benefit in PAH.
Materials and Methods
Animals
All mice were on a C57BL/6 background. IL-1R1/ (JAX
3245) and ApoE/ (JAX 2052) were obtained from Jack-
son Laboratories (Bar Harbor, ME), and ApoE//IL-
1R1/ mice were generated as previously described.16
Male mice, 10 to 12 weeks of age (7 per group), were fed
normal chow (4.3% fat, 0.02% cholesterol, and 0.28%
sodium) or a Paigen diet (18.5% fat, 0.9% cholesterol,
0.5% cholate, and 0.259% sodium) for 8 weeks. Diets
were supplied by Special Diet Services (Braintree, Essex,UK). All animal experiments were approved by the Uni-
versity of Sheffield Project Review Committee and con-
formed to UK Home Office ethical guidelines. Where
stated, human IL-1Ra or placebo (MTA 200517250-001;
Amgen, Inc., Thousand Oaks, CA) was administered by
Alzet (Cupertino, CA) 1004 osmotic mini pumps (100-L
reservoir; delivery rate, 0.1 L/h) set up to deliver 10 g/h
for 4 weeks, after an initial 4 weeks on diet. Pumps were
primed and implanted subcutaneously as per the manu-
facturer’s instructions.
Echocardiography
Echocardiography was performed using the Vevo 770
system (Visual Sonics, Toronto, Canada) using the
RMV707B scan head. Mice were placed on a heated
platform and covered to minimize heat loss. Rectal
temperature, heart rate, and respiratory rate were re-
corded continuously throughout the study. Anesthesia
was induced and maintained using isoflurane through
oxygen, maintaining heart rates at around 450 to 500
beats per minute whenever possible. The mice were
depilated and preheated ultrasound gel was applied
(Aquasonics 100 Gel; Parker Labs, Inc., Fairfield, NJ).
From the right parasternal long axis view, right ventricle
free wall parameters were determined using M-mode.
Standard parameters of the left ventricle were mea-
sured using 2-dimensional, M-mode and Doppler pulse
wave in the short axis view at the level of the papillary
muscles. Cardiac output was derived from flow and
annulus diameter at the junction between the outflow
tract and aortic valve. Cardiac index then was normal-
ized by body weight. Analysis was performed offline
using the accompanying software (Vevo 770, V3.0;
Visual Sonics). Measurements were taken during the
relevant phase of the cardiac cycle that did not coin-
cide with inspiration artifact.
Cardiac Magnetic Resonance Imaging
Anesthesia was induced and maintained using isoflu-
rane, and mice were placed in a custom-built acrylic
magnet capsule for imaging. Inside the capsule, a non-
magnetic ceramic heated hot air system (SAII–MR-com-
patible Heater System for Small Animals, Small Animal
Instruments, Stony Brook, NY) and rectal probe, inte-
grated into the physiological monitoring system, main-
tained the temperature of the animal. Mice were imaged
in a 7-Tesla magnet (BioSpecAVANCE, 310-mm bore,
magnetic resonance imaging system B/C 70/30; Bruker,
Coventry, UK), with a pre-installed, 12-channel, RT-shim
system (B-S30) and fitted with an actively shielded,
116-mm inner-diameter, water-cooled, 3-coil gradient
system (BioSpin magnetic resonance imaging GmbH
B-GA12; 400 mT/m maximum strength per axis with
80-s ramps; Bruker) to assess ventricular size after 8
weeks. A hydrogen-1 (1H) birdcage volume resonator
(300 MHz, 1 kW maximum, outer diameter, 114 mm;
inner-diameter, 72 mm; Bruker) placed at the iso-center
of the magnet was used for both radiofrequency trans-
mission and reception. A workstation configured for
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spectrometer. After field shimming, off-resonance cor-
rection and radiofrequency gain setting a triplane self-
gated (in slice navigator) Fast Low Angle SHot (FLASH)
sequence (TR, 44.5 ms; TE, 2.3 ms; flip angle, 7.5°;
field of view, 60 mm  60 mm; slice thickness, 1 mm;
matrix, 128  128) was used for subject localization. A
further self-gated FLASH sequence (Repetition Time,
5.8 ms; Echo Time, 2.3 ms; flip angle, 7.5°; field of
view, 35 mm  35 mm; slice thickness, 1.5 mm; matrix,
128  128) was used for single-slice cine magnetic
resonance imaging of the cardiac long axis. This was
used to plan for short-axis cine magnetic resonance
imaging (TR, 12.6 ms; TE, 2.3 ms; flip angle, 7.5°; field
of view, 35 mm*35 mm; slice thickness, 1.5 mm; matrix,
128*128). An in-parallel saturation slice was applied to
null the blood signal and increase ventricle wall con-
trast. For data processing, ParaVision IntraGate soft-
ware (Bruker) using Fourier filtering techniques18 was
used for navigator analysis and reconstruction of k-
space data.
Cardiac Catheterization
After echocardiography, left and right ventricular cath-
eterization was performed using a closed chest
method via the right internal carotid artery and the right
external jugular vein under isoflurane-induced anes-
thesia. Data were collected using a Millar ultra-minia-
ture pressure-volume PVR-1045 1F catheter (Millar In-
struments, Inc., Houston, TX) coupled to a Millar MPVS
300 and a PowerLab 8/30 data acquisition system (AD
Instruments, Oxfordshire, UK) and recorded using
Chart v7 software (AD Instruments). Pressure volume
analysis was performed using PVAN v2.3 (Millar Instru-
ments, Inc.).
RVH
RVH was measured using a modification of the Fulton
index19 by expressing the weight of the right ventricle
free wall relative to the left ventricle and septum.
Immunohistochemistry and Immunoblotting
Immediately after harvest, the left lung was perfusion
fixed via the trachea with 10% formal buffered saline by
inflation to 20 cm of H2O. The lungs then were pro-
cessed into paraffin blocks for sectioning. Paraffin-
embedded sections of lung were histologically stained
for Alcian Blue elastin van Gieson, immunohistochemi-
cally stained for -smooth muscle actin (M0851; Dako,
Cambridgeshire, UK) to visualize smooth muscle cells,
von Willebrand factor (A0082; Dako) to visualize endo-
thelial cells, CD3 (ab5690; Abcam, Cambridge, UK) to
visualize T-lymphocytes, CD4 (ab51312; Abcam) to
visualize helper T-lymphocytes, and F4/80 (ab6640;
Abcam) to visualize macrophages. Antibodies to os-
teoprotegerin (OPG) (ab73400; Abcam) and tumor
necrosis factor–related apoptosis-inducing ligand
(TRAIL) (ab2435; Abcam) also were used to localizeprotein expression to pulmonary vascular lesions.
Standard immunohistochemical techniques were ap-
plied. Mouse aortic tissue was used as a positive con-
trol for both von Willebrand factor and -smooth mus-
cle actin immunoreactivity, mouse spleen and human
tonsil were used as a positive control for all other
antibodies. In all cases, both IgG and no primary an-
tibody-negative controls were used. For immunoblot-
ting to detect IL-1R1 protein expression, whole-lung
lysates were run on Invitrogen (Paisley, UK) 4% to 12%
Bis-Tris gels as previously described,20 and incubated
with an IL-1R1 antibody (ab40774; Abcam) as per the
manufacturer’s instructions.
Quantification of Pulmonary Vascular
Remodeling
To assess the degree of pulmonary arterial remodeling,
microscopic images of Alcian Blue elastin van Gieson–
and -smooth muscle actin–stained lung sections were
analyzed using a NIS-Elements Basic Research software
(Nikon, Kingston upon Thames, Surrey, UK). The degree
of muscularization and the percentage of affected ves-
sels were calculated based on previously published
methods.21 In each lung section pulmonary arteries were
categorized as occluded (ie, only a slit-like, or no, lumen
remaining), muscularized (ie, with crescent, or complete
rings of muscle), or nonmuscular (ie, no apparent mus-
cle). The degree of muscularization was measured us-
ing the area of the media divided by the cross-sec-
tional area of the whole artery (media/CSA) and the
percentage of muscularization was calculated based
on the number of affected pulmonary arteries divided
by the total number of arteries multiplied by 100. Pul-
monary arteries also were categorized based on their
external diameter and divided into 3 groups: small
pulmonary arterioles with a diameter less than 50 m,
medium pulmonary arteries with a range in diameter
from 51 to 100 m, and large pulmonary arteries with a
diameter greater than 100 m.
Enzyme-Linked Immunosorbent and Cytometric
Bead Assays
To assess the levels of soluble cytokines in mouse
serum we used Cytometric Bead Assay Flex sets (BD
Biosciences, Oxford, UK) for IL-1 , IL-6, and regu-
lated on activation normal T-cell expressed and se-
creted (RANTES), and an enzyme-linked immunosor-
bent assay for OPG (R&D Systems, Abingdon, UK).
qPCR
To assess the level of gene expression in RNA isolated
from mouse lung and aorta, RNA was extracted using
RNA/DNA/protein isolation kits (Norgen Biotek, Thor-
old, Ontario, Canada), and reverse transcribed using
Superscript III (Invitrogen). Gene expression was mea-
sured by performing TaqMan PCR using Gene Expres-
sion MasterMix and Gene Expression Assays (Applied
ermates
01.
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Mm00434237_m1 (exon 6/7) and Mm01226959_m1
(exon 1/2)], OPG (assay ID Mm00435452_m1), and
TRAIL (assay ID Mm00437174_m1). Gene expression
was normalized to 18S ribosomal RNA (assay ID
999999011) using the CT comparative quantification
method as previously described.20
Results
Right Ventricular HemodynamicMeasurements Are
Abnormal in Paigen Diet–FedApoE/Mice and
More Exaggerated inApoE//IL-1R1/Mice
Fat feeding (Paigen diet) to IL-1R1/ mice had no effect
on RVSP (Figure 1A) or right ventricular end-diastolic
pressure (Figure 1C). In contrast, ApoE/ mice fed the
high-fat diet (Paigen) developed a significant increase in
both RVSP (Figure 1A) and right ventricular end-diastolic
pressure (Figure 1C) compared with chow-fed litter-
mates. Surprisingly, double-deficient ApoE//IL-1R1/
fed the same diet also showed a significantly increased
RVSP (Figure 1A) and right ventricular end-diastolic pres-
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Figure 1. Hemodynamic characterization. Bar graphs show RVSP in mm H
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by analysis of variance followed by Bonferroni post hoc analysis. ***P  0.0sure (Figure 1C) compared with chow-fed controls. In-triguingly, the RVSP observed in the Paigen diet–fed
ApoE//IL-1R1/ mice was significantly higher than in
ApoE/ mice on the same diet (Figure 1A). Increased
RV contractility, as measured by dP/dtmax (derivative of
the maximal rate of ventricular pressure rise during iso-
volumetric contraction phase), also was increased signif-
icantly in Paigen diet–fed ApoE/ mice and further in-
creased in ApoE//IL-1R1/ mice (Figure 1E). Doppler
ultrasound assessment of pulmonary artery acceleration
time, which has an inverse relationship to RVSP, also was
decreased in both the Paigen diet–fed ApoE/ and
ApoE//IL-1R1/ mice, compared with chow-fed litter-
mates (Figure 1H).
To confirm this increase in RVSP was arising from the
pulmonary circulation, left ventricular pressures also
were measured. No significant changes in left ventricular
end-systolic pressures or left ventricular end-diastolic
pressures were observed (Figure 1, B and D). Similarly,
there were no changes in LV contractility, as measured
by dP/dtmax, in any group (Figure 1F). There was a sig-
nificantly reduced cardiac index between the chow-fed
ApoE/ and ApoE//IL-1R1/ mice but there was no
significant effect of the Paigen diet on the cardiac index
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AJP October 2011, Vol. 179, No. 4Right Ventricular Remodeling in Paigen Diet–Fed
ApoE/ and ApoE//IL-1R1/ Mice
Volume analysis of the right ventricle, using a conduc-
tance catheter, showed a significant increase in dV/dtmax
in the Paigen diet–fed ApoE/ mice, and ApoE//IL-
1R1/ mice compared with chow-fed littermates (Figure
2A), although a statistically significant increase in RVH
was observed only in Paigen diet–fed ApoE//IL-1R1/
mice (Figure 2B). In addition, the increase in dV/dtmax
and the degree of RVH was significantly greater for the
Paigen diet–fed ApoE//IL-1R1/ mice compared with
Paigen diet–fed ApoE/ mice. Significant atrial enlarge-
ment also was observed in the Paigen diet–fed ApoE//
IL-1R1/ mice compared with chow-fed littermates, al-
though we did not dissect down further to determine
whether this primarily was caused by right atrium en-
largement (Table 1). Echocardiographic imaging re-
vealed a trend for an increase in the internal diameter of
the right ventricle in diastole (Figure 2C), with no ob-
served changes in the left ventricle (Figure 2D). Image
processing of H&E-stained hearts, and live cardiac mag-
netic resonance imaging at the level of the papillary mus-
cles, further illustrated the increase in internal right ven-
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Figure 2. Assessment of right ventricular volume and hypertrophy. Bar gra
volume cardiac catheterization (A), Fulton Index of RVH (B). Right ventricular
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muscles (E). Right ventricle internal area is colored blue. Bars represent mea
Statistical differences between Paigen diet–fed mice are shown as assessedtricular size without thickening of the right ventricular wall,in the Paigen diet–fed ApoE/, and particularly the
ApoE//IL-1R1/ mice (Figure 2E).
Increased Pulmonary Vascular Remodeling in
Fat-Fed ApoE/ and ApoE//IL-1R1/
Mice
Histologic and immunohistochemistry analysis of serial
lung tissue samples revealed no evidence of any pulmo-
nary vascular remodeling in either the ApoE/ or ApoE//
IL-1R1/ mice fed a regular chow diet. Similarly, there
was no evidence of any effect of the Paigen diet on
pulmonary vascular remodeling in the IL-1R1/ mice
(data not shown). Analysis of lungs from Paigen diet–fed
ApoE/ and ApoE//IL-1R1/ mice did, however, re-
veal evidence of a severe pulmonary vasculopathy, in-
cluding heavily muscularized and obliterative lesions in
the small resistance pulmonary arteries (50 m) in
both genotypes. Further assessment of the extent of
pulmonary vascular remodeling by quantifying the de-
gree of muscularization as previously described22 sub-
sequently was performed. Analysis of the media/CSA
ratio of the whole artery or arteriole, and the percent-
age of nonmuscularized, muscularized, and obliter-
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(100 m). The media/CSA ratio of the small pulmo-
nary arteries and arterioles (50 m) in both the
Paigen diet–fed ApoE/ and ApoE//IL-1R1/ mice
was increased significantly (Figure 3A) compared with
chow-fed controls. Although there was no significant
difference in media/CSA between the Paigen diet–fed
mice, segmentation of small pulmonary arteries into
those with no signs of muscularization, muscularized,
or those obliterated/fully occluded showed a signifi-
cant decrease in nonmuscular arteries, and a signifi-
cant increase in muscularized lesions in the Paigen
diet–fed ApoE//IL-1R1/ mice compared with the
ApoE/ mice (Figure 3B). In the medium-sized pul-
monary arteries (51 to 100 m), there was a significant
increase in the media/CSA in the Paigen diet–fed
ApoE/ and this was increased further in the ApoE//
IL-1R1/ mice (Figure 3C). There were no signs of mus-
Table 1. Heart Weight Measurements
IL-1R1/
Chow Paigen
Body weight, g 28.8 0.8 28.7  0.9 28
Total heart, mg 116.1 7.0 98.7  3.5 129
Atria, mg 10.7  0.6 8.5  0.2 12
RV, mg 20.4  2.5 20.5  1.1 21
LV&S, mg 99.0  6.2 98.8  4.4 98
RV/LV&S 0.20  0.01 0.21  0.02 0.
RV/body weight 0.70  0.07 0.71  0.05 0.
All values represent mean  SEM, n  3 to 7.
*P  0.05 chow versus Paigen.
†P  0.05 ApoE/ Paigen versus ApoE//IL-1R1/ Paigen.
‡P  0.001 chow versus Paigen.
§P  0.01 ApoE/ Paigen versus ApoE//IL-1R1/ Paigen.
¶P  0.01 chow versus Paigen.
RV, right ventricle; LV&S, left ventricle plus septum.
Figure 3. Quantification of pulmonary artery muscularization. Bar charts sh
(A, C, and D), and the percentage of affected vessels (B). A and B: Data fro
100 m in diameter. D: Data from vessels more than 100 m in diameter. Ba
with chow-fed littermates. Statistical differences between Paigen diet–fed mice are
analysis.cularization in the large (100 m) pulmonary arteries in
the Paigen diet–fed ApoE/ mice but there was a sig-
nificant increase in the media/CSA of the Paigen diet–fed
ApoE//IL-1R1/ mice (Figure 3D). We have hypothe-
sized that the more severe pulmonary hemodynamic
changes and RVH seen in the Paigen-fed ApoE//IL-
1R1/ mice compared with the Paigen diet–fed
ApoE/ mice are related to the more extensive remod-
eling of the small resistance vessels, although changes
seen in the more proximal pulmonary vasculature also
may contribute.
The lesions show many features of human disease
including dysregulated elastin and increased collagen
as shown by the Alcian Blue elastin van Gieson stain-
ing (Figure 4) and disorganized smooth muscle cell
proliferation. Increased smooth muscle cell accumula-
tion (-smooth muscle actin) was observed in hyper-
trophied medial layers, and within the neointima of
ApoE/ ApoE//IL-1R1/
Paigen Chow Paigen
.8 30.9  1.1 30.3  0.9 32.2  1.1
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0.8 92.0  8.2 97.6  7.04 114.1  7.6
.01 0.23  0.01 0.21  0.01 0.29  0.03*
.03 0.72  0.03 0.66  0.03 0.94  0.09†¶
e degree of medial wall thickness as a ratio of total vessel size (media/CSA)
onary arteries less than 50 m in diameter. C: Data from vessels from 51 to
sent mean  SEM, n  4 to 7. *P  0.05, **P  0.01, ***P  0.001 comparedChow
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65  0owing th
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rs represhown as assessed by analysis of variance followed by Bonferroni post hoc
rway ep
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AJP October 2011, Vol. 179, No. 4lesions. All lesions showed an intact endothelium (von
Willebrand factor) (Figure 4). To determine whether
these obliterative pulmonary arterial lesions were as-
sociated with infiltration of inflammatory cells we per-
formed immunohistochemistry for macrophages and T
lymphocytes. By using F4/80 as a marker for macro-
phages we failed to see a significant association of F4/80-
positive cells with any of the remodeled pulmonary arteries
(data not shown). The vascular and perivascular regions
of lung from the chow-fed mice showed very little T-
lymphocyte infiltration, however, there was an influx of
CD3 cells to perviscular regions of remodeled pulmo-
nary arteries in fat-fed ApoE/ and ApoE//IL-1R1/
mice (Figure 4). Only a few isolated CD4 cells were
observed in the perivascular regions of both Paigen diet–
Figure 4. Representative photomicrographs of serial lung sections from ch
Gieson (ABEVG) or immunostained for -smooth muscle actin (-SMA), von
or Paigen diet displayed some nonspecific CD3 immunoreactivity in the ai
magnification, 400. Scale bar  50 m.fed ApoE/ and ApoE//IL-1R1/ mice (Figure 4).Inflammatory Mediators Are Up-Regulated in
the Paigen Diet–Fed ApoE//IL-1R1/ Mice
To investigate possible mechanisms that might be driving
disease pathogenesis, particularly in the Paigen diet–fed
ApoE//IL-1R1/ mice, we performed a series of se-
rum cytokine cytometric bead assays and enzyme-linked
immunosorbent assays. Analysis of inflammatory media-
tors in these mice revealed that feeding of the Paigen diet
was associated with significantly higher levels of IL-1
(Figure 5A) and IL-6 (Figure 5B) in both ApoE/ and
ApoE//IL-1R1/ mice. Although there was a trend for
increased RANTES in the Paigen-fed ApoE/ mice this
was not significant (Figure 5C). Interestingly, this re-
sponse was heightened significantly in the Paigen diet–
d Paigen diet–fed mice. Sections were stained with Alcian Blue elastic van
nd factor (vWF), CD3, or CD4. The ApoE//IL-1R1/mice fed either chow
ithelium. Representative heavily muscularized arteries are shown. Originalow- an
Willebrafed ApoE//IL-1R1/ mice compared with ApoE/
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AJP October 2011, Vol. 179, No. 4mice for IL-6 (Figure 5B) and RANTES (Figure 5C), sug-
gesting that the Paigen diet–fed ApoE//IL-1R1/mice
show an exaggerated inflammatory phenotype despite
lacking IL-1R1.
Putative Biomarkers of PAH Are Increased in
Paigen-Fed ApoE/ and ApoE//IL-1R1/
Mice
We previously reported that human pulmonary vascular
lesions from patients with idiopathic PAH are associated
with medial immunoreactivity for both TRAIL and OPG.23
We investigated expression of these molecules in this
mouse model of severe PAH. Little OPG expression was
observed in chow-fed mice. Diffuse medial staining and
strong cellular immunoreactivity for OPG was observed
within lesions from both Paigen diet–fed ApoE/ and
ApoE//IL-1R1/ mice (Figure 6A). Weak TRAIL im-
munoreactivity was observed within the epithelial and
endothelial cells of chow-fed ApoE/ and ApoE//IL-
1R1/ mouse lungs (Figure 6A). There were in-
creased TRAIL-positive cells within the media and
perivascular tissue of remodeled arteries from both the
Paigen diet–fed ApoE/ and ApoE//IL-1R1/ mice
(Figure 6A). This appeared to be de novo expression
because TaqMan PCR on whole-lung extracts from
these mice showed TRAIL expression to be increased
significantly in both Paigen diet–fed ApoE/ and
Figure 5. Serum cytokine levels are increased in Paigen diet–fed ApoE//
IL-1R1/ mice. Bar graphs show serum levels of IL-1 (A), IL-6 (B), and
RANTES (C). Bars represent mean  SEM, n  4 to 7. *P  0.05, **P  0.01
compared with chow-fed littermates. Statistical differences between Paigen
diet–fed mice are shown as assessed by analysis of variance followed by
Bonferroni post hoc analysis.ApoE//IL-1R1/ mice (Figure 6B). OPG expressionalso was increased significantly in both Paigen diet–
fed ApoE/ and ApoE//IL-1R1/ mice, and the
level of gene expression in Paigen diet–fed ApoE//
IL-1R1/ mice was significantly higher than the
ApoE/ mice (Figure 6C). Because OPG is a naturally
secreted molecule and we previously reported in-
creased serum OPG in patients with Idiopathic
(IPAH),23 we next performed an OPG enzyme-linked
immunosorbent assay on the mouse serum. OPG levels
were significantly higher in both Paigen diet–fed
ApoE/ and ApoE//IL-1R1/ mice compared with
chow-fed littermates. The circulating levels of OPG in
the Paigen diet–fed ApoE//IL-1R1/ mice were also
significantly higher than the ApoE/ mice (Figure 6D).
These data confirm our initial studies in human PAH
and provide further evidence for a role of both mole-
cules in disease pathogenesis, and for OPG as a po-
tential biomarker of disease. BMP-R2 mutations are
clearly important in human forms of IPAH24–26 and
reduced BMP-R2 levels have similarly been reported in
animal models of PAH.27 Because we previously re-
ported that levels of OPG and TRAIL can be regulated
by impaired or reduced BMP-R2 expression as well as
increased IL-1 signaling,23 we next sought to deter-
mine whether the increased expression of these pro-
teins was associated with reduced expression of
BMP-R2 in this model. BMP-R2 levels were reduced
significantly in both Paigen diet–fed ApoE/ and
ApoE//IL-1R1/ mice compared with chow-fed lit-
termates (Figure 6E).
Inflammatory Mechanisms Drive PAH
Phenotype in Fat-Fed ApoE//IL-1R1/ Mice
Interestingly, the Paigen diet–fed ApoE//IL-1R1/
compared with Paigen diet–fed ApoE/ mice showed
increased levels of IL-1 as well as increased expression
of molecules downstream of IL-1 signaling such as IL-6,
RANTES (Figure 5, B and C), and OPG (Figure 6C).
TaqMan PCR for IL-1R1 mRNA in the lungs of both the
ApoE/ and ApoE//IL-1R1/ mice revealed signifi-
cant expression of IL-1R1 mRNA in RNA isolated from the
lungs of all mice (Figure 7A). This led us to speculate that
an IL-1R1 mRNA and a putative protein may be produced
in the lungs of ApoE//IL-1R1/ mice. Further investi-
gation revealed that the IL-1R1 probe in the TaqMan
assay annealed across the exon 6/7 boundary, and that
the IL-1R1/ mouse within our experiments was gener-
ated by removing the sequence for amino acids 4 to 146,
equating to exons 1 and 2.28 We confirmed that these
exons were indeed missing from the ApoE//IL-1R1/
mice using an alternative TaqMan probe set (Figure 7B).
It is known that there are multiple promoter sites in the
human17 and mouse29 IL-1R1 gene that can regulate
tissue-specific expression. We were able to show lung-
specific expression of this IL-1R1 form using a TaqMan
assay for exon 6/7 and expression of IL-1R1 was evident
in the lungs but not aorta of ApoE//IL-1R1/ mice
(Figure 7C). This indicates a degree of tissue specificity
for the alternative IL-1R1 transcript. As expected, mRNA
iet–fed
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AJP October 2011, Vol. 179, No. 4for exon 2/3 was not found in ApoE//IL-1R1/ lung or
aorta (Figure 7D). We next sought to determine whether
this putative mRNA transcript present within the lungs of
these mice resulted in protein expression. Western im-
munoblotting of whole-lung lysates from both ApoE/
and ApoE//IL-1R1/ mice using an anti–IL-1R1 anti-
body revealed immunoreactivity in both strains of mice,
indicating the presence of translated protein. These data
show that in this model, lung-specific expression of a
putative alternate IL-1R1 receptor form may contribute to
the severe PAH phenotype observed in these mice.
IL-1ra (Anakinra) Prevents Progression of
PAH in Paigen Diet–Fed ApoE/ and
ApoE//IL-1R1/ Mice
To further investigate IL-1–driven inflammatory mecha-
nisms in both Paigen diet–fed models, and to determine
whether the alternative IL-1R1 transcript may be functional,
we implanted Alzet mini osmotic pumps to deliver either
placebo or IL-1ra (anakinra) at 10 g/h for 4 weeks. Treat-
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We next looked to see whether the increased levels of
IL-1, IL-6, RANTES, and OPG similarly were reduced
by treatment with IL-1ra. We found no significant in-
crease in serum levels of IL-1 (Figure 8D), IL-6 (Figure
8E), RANTES (Figure 8F), or OPG (Figure 8G) in the
IL-1Ra-treated, Paigen diet-fed mice compared to
chow-fed controls. There was also a significant reduc-
tion in OPG gene expression in whole-lung lysates from
the IL-1ra–treated mice compared with placebo-
treated littermates (Figure 8H). These data suggest
that IL-1ra effectively blocks the progression of PAH in
this model and that this is associated with reduced levels of
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In this study we describe a murine model of severe PAH
adapted from the ApoE/ model originally published by
Hansmann et al.8 We show that by feeding the more
aggressive atherogenic Paigen diet, ApoE/ mice de-
velop severe PAH. A continuing challenge for research
into the mechanisms important in the pathogenesis of
PAH has been the absence of a murine, preclinical model
that recapitulates accurately all of the clinical and patho-
logic features of human pulmonary hypertension (PH).30
To our knowledge, the severity of PH in our mouse model
is greater both hemodynamically and with regard to pul-
monary vascular remodeling than previously published
murine models, including (but not exclusively) schisto-
somiasis models,22 ALK531 and genetically modified
mouse models based on dysfunctional BMP-R2,32,33 va-
sointestinal peptide (VIP) knockout mice,34 and mice
overexpressing IL-613 and S100A4/Mts1.35
Of particular note in this model is that ApoE//IL-
1R1/ mice have dissociation between the two inflam-
matory vascular phenotypes studied. In these animals,
systemic atherosclerosis is 40% less at the aortic sinus
than ApoE/ counterparts,16 and there is a 50% in-
crease in RVSP compared with ApoE/. We show that a
potential explanation for this unexpected effect is a pu-
tative, alternative IL-1R1 transcript expressed in the lungs
but not aorta of ApoE//IL-1R1/ mice. In our model,
this alternative IL-1R1 transcript appears to have the ca-
pacity to drive the pulmonary vascular phenotype. We
have shown, at least in part, functionality of this receptor
in these mice by blocking the progression of disease
through the administration of IL-1ra (anakinra). These
data provide further evidence that IL-1 is important in the
pathogenesis of PAH and suggest that targeting IL-1 may
have therapeutic potential in the setting of PAH.
The implication that IL-1 signaling may play an impor-
tant role in PAH pathogenesis has been highlighted pre-
Figure 7. Expression of an alternative IL-1R1 transcript in ApoE//IL-1R1/
6/7 (A), and exons 2/3 in whole-lung RNA samples (B). Comparison of lung
(C), and exons 2/3 (D). E: Western immunoblot for IL-1R1 in whole-lung ly
normalized using CT with 18S rRNA as the endogenous control gene. Bars
as assessed by analysis of variance followed by Bonferroni post hoc analysiviously. Biomarker studies have shown increased serumlevels of many inflammatory cytokines, including IL-1 and
the downstream cytokine IL-6.36,37 Treatment of rats with
the naturally occurring IL-1ra has been shown to protect
against development of monocrotaline-induced PAH, but
interestingly not hypoxia,38 and overexpression of IL-6 in
mice leads to PAH.13
The exaggerated pulmonary hypertension, despite re-
duced atherosclerosis, indicates that some lung-specific
IL-1R1 signaling remains in our ApoE//IL-1R1/
mouse. IL-1R1/ transcript analysis suggests that tissue
specificity arises from alternative expression of these
transcripts, and that an artificial alternative transcript is
still expressed that actively signals IL-1, and is inhibited
by IL-1ra. These data suggest that there are unique as-
pects of IL-1 signaling in the lung and we note that a
recent report on a genome-wide association study of
asthma implicated a single-nucleotide polymorphism af-
fecting the IL-1R1 gene.39 These data therefore raise
significant opportunities for IL-1 blockade in PAH and
other lung diseases, and also caution the interpretation of
lung phenotype data that are generated using the current
IL-1R1/ mouse.
In keeping with published data from studies performed
in end-stage human IPAH, we also observed an increase
in gene expression and/or serum levels of proteins known
to be activated by IL-1, and proposed to be important in
the pathogenesis of PAH including IL-6,11 RANTES,10
OPG, and TRAIL.23 Indeed, the co-localization of OPG
and TRAIL expression to the remodeled pulmonary arter-
ies in this new mouse model was almost identical to our
findings in human PAH.23 PPAR signaling and adi-
ponectin are proposed to play an important role in the
development of PAH in Western diet–fed ApoE/
mice.8,9 There are also links between IL-1 and PPAR
signaling including in the suppression of IL-1–induced
smooth muscle cell proliferation,40 and between PPAR
signaling and the regulation of both OPG41 and TRAIL.42
Gene expression of IL-1R1 using TaqMan primer/probe sets that cross exons
a expression of IL-1R1 using TaqMan primer/probe sets that cross exons 6/7
lated from three ApoE/ and three ApoE//IL-1R1/ mice. All data are
nt mean SEM, n  4 to 7. Statistical differences between groups are shown
0.05 and ***P  0.001. lungs.
and aort
sates isoFurther studies currently are underway to fully determine
SEM, n
 0.01
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TRAIL, play in disease pathogenesis of this and other
established models of pulmonary hypertension.
Very recent reports have suggested that the ingredient
cholate in the Paigen diet formulation is responsible for
the formation of lung granulomas in a proposed mouse
model of sarcoidosis43 and the formation of multinucle-
ated giant cells within atherosclerotic plaques.44 Al-
though we observed some early granulomas within the
lungs of our mice, we detected no difference in these
across our mouse genotypes, suggesting that the two
lung pathologies are not intrinsically linked, at least at the
earlier time points used for this study (8 weeks on diet
compared with 16 weeks).
In this current study we have shown that treatment with
IL-1ra as disease is developing prevents further disease
progression. Although the ability of IL-1ra treatment to
fully reverse human PAH is difficult to fully ascertain in
animal models, prevention or slowing disease progres-
sion in patients would in itself be highly desirable. IL-1ra
Figure 8. Treatment with IL-1ra reversed PAH. Bar graphs show RVSP meas
(media/CSA) (B), RVH (C), and serum levels of IL-1 (D), IL-6 (E), RANTES (
with 18S rRNA as the endogenous control gene (H). Bars represent mean 
analysis of variance followed by Bonferroni post hoc analysis. *P  0.05, **P(anakinra/Kineret, Amgen, Thousand Oaks, CA) currentlyis used for the treatment of rheumatoid arthritis and is
being studied for its efficacy in a number of clinical trials
ranging from diabetes45 and left ventricular remodeling
after STEMI.46
One limitation of our model is that the levels of right
ventricular remodeling are less than reported by Hans-
mann et al8 in Western-diet fed ApoE/ mice. This rela-
tively mild RVH appears to be out of proportion to the
degree of pulmonary vascular remodeling and increased
in right heart pressures. This is particularly surprising
given that we can routinely measure RVH in the hypoxic
mouse model that generates substantially lower RVSP.
We have investigated this phenomenon intensively
through the use of invasive pressure-volume catheteriza-
tion and noninvasively with dedicated small animal ultra-
sound and magnetic resonance imaging to further verify
this finding. All of the data obtained points to a right
ventricle that, although being slightly enlarged, is coping
well with the high demands made on it by the increased
pulmonary vascular resistance. We hypothesize that this
mm Hg (A), the degree of medial wall thickness as a ratio of total vessel size
(G), and TaqMan expression of OPG in whole lung normalized using CT
 4 to 7. Statistical differences between groups are shown as assessed by
, and ***P  0.001.ured in
F), OPGmay be owing in part to the altered metabolic condition of
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that we will continue to investigate. This phenomenon is
not unique to this study, other investigators have reported
increased right heart pressures in transgenic mice with-
out the occurrence of RVH, particularly without exposure
to hypoxia.47 Studies examining the effect of norepineph-
rine infusion in congestive heart failure models also have
highlighted significant increases in both RVSP and RV
dP/dtmax with no detectable increase in RVH.
48 Interest-
ingly, in this study Barth et al do report a significant
increase in left ventricular hypertrophy despite no in-
crease in left ventricular pressure and implicate IL-1/IL-
6–mediated collagen I and III in this process. Further
evidence for the importance of IL-1 in cardiac remod-
eling comes from murine studies describing spontane-
ous left ventricular hypertrophy leading to heart failure
in transgenic mice after cardiac-specific overexpres-
sion of IL-1 .49 These studies highlight the complexity
of cardiac remodeling and perhaps highlight other key
drivers for hypertrophy other than hemodynamic
changes alone. Whether differential IL-1 signaling in
the two ventricles is responsible for this certainly war-
rants further investigation.
The accessibility of ApoE/ mice and atherosclerotic
diets, combined with the high degree of pulmonary vas-
cular remodeling, make this a practical and alternative
model for many laboratories interested in studying the
role of a particular gene or drug on the pathogenesis of
PAH. Furthermore, despite the severe hemodynamic and
histopathologic phenotype, this models displays favor-
able right ventricular adaptation, and thus also may serve
as an additional investigative tool to study the right ven-
tricle. These findings highlight the potential role of IL-1
signaling in PAH and raise the possibility and importance
of alternative signaling in the lung. Targeting IL-1, which
is upstream of most vascular inflammatory pathways and
has proven systemic anti-inflammatory effects, may be a
viable alternative treatment strategy to slow disease pro-
gression in PAH, particularly when associated with other
inflammatory disorders.
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